‘Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study’, also known as GRADE, is a multicenter, parallel-group clinical trial that is designed to compare the major drug classes that are currently used to treat type 2 diabetes.
“GRADE will inform the choice of the most durable diabetes medication added to metformin to achieve and maintain good glycemic control and prevention long-term complications while preserving the quality of life of patients with type 2 diabetes in the U.S. and beyond,” said Dr. Hermes Florez, professor at the Miller School of Medicine and director of the GRECC at the Miami Veterans Affairs Healthcare System (VAHS).
There is a total of 5,047 participants are currently enrolled in GRADE. Their baseline characteristics were recently reported in Diabetes Care, an American Diabetes Association (ADA) journal. Researchers from 36 academic and medical centers in the United States, including the University of Miami Department of Public Health Sciences and the GRECC at the VAHS. To assess the broader generalizability of GRADE, researchers also compared the cohort to a National Health and Nutrition Examination Survey cohort who met GRADE’s inclusion criteria.
The report provided a description of the large randomized cohort who were 30 years of age or older, who have had type 2 diabetes for less than 10 years and who have relied primarily on metformin for treatment. The participants had a glycosylated hemoglobin of 6.8 to 8.5 percent at baseline. There were approximately 20 percent African Americans and 18 percent Hispanics who are at high-risk for diabetes and its complications and who are similar in age, such as at around 57 years. They had a diabetes duration of approximately four years.Tags: Friday Letter Submission, Publish on December 20